Records are supplied by study sponsors and investigators. A registry listing is not an endorsement or a guarantee of safety, availability or eligibility.
WCR feed checked: Nov 12, 2026.
RecruitingNCT07928388
Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Phase 32 years - Not specifiedPalo Alto, California, United States +4 Continued access to MC-1 is required by subjects who have participated in the MEND-PNPO study, as no other pharmaceutical grade P5P is currently commercially available. The protocol duration is planned for until the finished product is commercially a…
RecruitingNCT07613775
Gingival Recession
Not applicable18 years - Not specifiedRibeirão Preto, São Paulo, Brazil Gingival recession is a clinical condition in which the gingival margin is displaced apically, exposing the root surface. This condition may be associated with esthetic concerns, dentin hypersensitivity, and difficulties in oral hygiene. Subepithelia…
RecruitingNCT06479837
Staphylococcal Infections
Observational2 years - 120 yearsBethesda, Maryland, United States Background: Staphylococcus aureus (S.aureus) are bacteria that can make people sick. Sometimes, an S. aureus infection can develop inside the spine; these infections can lead to paralysis and death. Researchers do not know how S. aureus interacts wit…
CompletedNCT06893926
s100b · Hypoxia-Ischemia, Brain · Fetal Growth Restriction (FGR)
Observational18 years - Not specifiedWarsaw, Poland S100B protein is a biomarker that increases following central nervous system (CNS) damage. Measuring this protein's levels may allow for the early identification of infants at high risk for developmental abnormalities, such as fetal growth restrictio…
Active, not recruitingNCT05409989
Intracranial Aneurysm
Not applicable22 years - 75 yearsHollywood, Florida, United States +20 The objective of this study is to generate contemporaneous clinical data to facilitate a reasonable comparison of the performance of the FRED™ X™ device with the performance of the FRED™ device. The data generated from this study will be compared to …
Active, not recruitingNCT06217185
HER2-positive Breast Cancer · Advanced Breast Cancer
Phase 418 years - 70 yearsShijiazhuang, Hebei, China This is a multi-center real-world study, in which patients who meet the inclusion criteria will receive treatment with Pyrotinib + Trastuzumab + Taxanes. Taxanes will be used for 6-8 cycles or discontinued due to intolerable Adverse Events (AEs), aft…
CompletedNCT04511286
Somatic Symptom Disorder
Not applicable18 years - Not specifiedStockholm, Sweden This study investigates the feasibility of a general exposure-based treatment protocol that is intended to work for a large variety of patient groups with a clinically significant preoccupation with physical symptoms. This is a prospective single-gro…
RecruitingNCT07929922
Anterior Cruciate Ligament (ACL) Tear
Not applicable15 years - 40 yearsColumbus, Ohio, United States +1 The ASPIRATE trial is a randomized controlled trial evaluating the effects of pre- and post-operative knee joint aspiration in patients with an ACL injury. The study aims to determine if removing knee joint fluid can mitigate the increasing inflammat…
CompletedNCT06710483
Intellectual Disability, Variable
Not applicable12 years - 18 yearsBoston, Massachusetts, United States This randomized clinical trial is an innovative pilot project to determine the acceptance and impact of telehealth visits on youth with intellectual and developmental disabilities (IDD), their caregivers, and dentists. The impact of the telehealth vi…
CompletedNCT01207492
Pigmented Villonodular Synovitis · Diffuse-type Giant Cell Tumor · Tenosynovial Giant Cell Tumor
Phase 218 years - Not specifiedSanta Monica, California, United States +5 Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia. Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS). In this research study the inve…
Not yet recruitingNCT07929857
Hair and Scalp Health
Not applicable18 years - Not specifiedAix-en-Provence, France +1 Cellbooster® Hair (CBH) is a class III medical device, CE marked, HA-based injectable using the patented CHAC Technology. It consists of stabilized Hyaluronic Acid 18mg (6mg/ml) with Amino Acids and Vitamins, and minerals (zinc, copper). The medical …
RecruitingNCT07886970
Healthy · Health Knowledge, Attitudes, Practice
Not applicable18 years - 40 yearsBolu, Merkez, Turkey (Türkiye) Interactions with virtual content can enhance the creation and retention of knowledge. While some studies have found that learning methods involving the body-such as tactile manipulation-can lead to deeper understanding and higher achievement scores,…
Retrieved from ClinicalTrials.gov: Nov 12, 2026. Overall study status may differ from a particular location’s status.
